Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

[1]  A. Chabes.  dNTPs and maintenance of genome stability , 2019 .

[2]  Li-li Wang,et al.  Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes , 2018, Annals of Hematology.

[3]  Alexandra G. Smith,et al.  The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.

[4]  B. Stillman,et al.  The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592 , 2018, Cell cycle.

[5]  Tae Kon Kim,et al.  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.

[6]  V. Costanzo,et al.  SAMHD1 acts at stalled replication forks to prevent interferon induction , 2018, Nature.

[7]  L. Kaderali,et al.  The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1 , 2018, Proceedings of the National Academy of Sciences.

[8]  L. Bullinger,et al.  Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia , 2018, Expert review of hematology.

[9]  A. Scheel,et al.  Current PD-L1 immunohistochemistry for non-small cell lung cancer. , 2018, Journal of thoracic disease.

[10]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[11]  Y. Xiong,et al.  A Cyclin-Binding Motif in Human SAMHD1 Is Required for Its HIV-1 Restriction, dNTPase Activity, Tetramer Formation, and Efficient Phosphorylation , 2018, Journal of Virology.

[12]  L. Hesson,et al.  AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo , 2017, Leukemia.

[13]  E. Rock,et al.  Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. , 2017, The Lancet. Oncology.

[14]  Allyson E. Koyen,et al.  SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. , 2017, Cell reports.

[15]  L. Pleyer,et al.  Azacitidine in adult patients with acute myeloid leukemia. , 2017, Critical reviews in oncology/hematology.

[16]  T. Helleday,et al.  SAMHD1 protects cancer cells from various nucleoside-based antimetabolites , 2017, Cell cycle.

[17]  C. Drenberg,et al.  OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. , 2017, Cancer research.

[18]  S. Kearsey,et al.  A Critical Balance: dNTPs and the Maintenance of Genome Stability , 2017, Genes.

[19]  S. Lehmann,et al.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies , 2017, Nature Medicine.

[20]  J. Nettles,et al.  Substrates and Inhibitors of SAMHD1 , 2017, PloS one.

[21]  L. Kaderali,et al.  SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia , 2016, Nature Medicine.

[22]  J. Stivers,et al.  Single-Stranded Nucleic Acids Bind to the Tetramer Interface of SAMHD1 and Prevent Formation of the Catalytic Homotetramer. , 2016, Biochemistry.

[23]  Anne-Kathrin Garz,et al.  A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers , 2016, Clinical Epigenetics.

[24]  V. Hornung,et al.  Phosphorylation of murine SAMHD1 regulates its antiretroviral activity , 2015, Retrovirology.

[25]  Y. Xiong,et al.  Impaired dNTPase Activity of SAMHD1 by Phosphomimetic Mutation of Thr-592*♦ , 2015, The Journal of Biological Chemistry.

[26]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[27]  Y. Lyubchenko,et al.  SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity , 2015, Nucleic acids research.

[28]  R. Garzon,et al.  Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. , 2015, Blood.

[29]  J. Stivers,et al.  A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase , 2015, Journal of biomolecular screening.

[30]  N. Ferreirós,et al.  Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry , 2015, Analytical and Bioanalytical Chemistry.

[31]  Mark N. Wass,et al.  Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen , 2015, Scientific Reports.

[32]  L. Ratner,et al.  Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. , 2015, Cell host & microbe.

[33]  L. Pleyer,et al.  Digging deep into “dirty” drugs – modulation of the methylation machinery , 2015, Drug metabolism reviews.

[34]  Y. Xiong,et al.  Structural basis of cellular dNTP regulation by SAMHD1 , 2014, Proceedings of the National Academy of Sciences.

[35]  B. Clotet,et al.  Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells , 2014, The Journal of Immunology.

[36]  S. McClue,et al.  The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma , 2014, Oncotarget.

[37]  Kirsten Grønbæk,et al.  Predicting response to epigenetic therapy. , 2014, The Journal of clinical investigation.

[38]  A. Gronenborn,et al.  Mechanism of Allosteric Activation of SAMHD1 by dGTP , 2013, Nature Structural &Molecular Biology.

[39]  James A. Thomson,et al.  Match criteria for human cell line authentication: Where do we draw the line? , 2013, International journal of cancer.

[40]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[41]  T. Helleday,et al.  5-Aza-2′-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair , 2013, Nucleic acids research.

[42]  Li Wu,et al.  Promoter Methylation Regulates SAMHD1 Gene Expression in Human CD4+ T Cells* , 2013, The Journal of Biological Chemistry.

[43]  R. König,et al.  SAMHD1 restricts HIV-1 infection in resting CD4+ T cells , 2012, Nature Medicine.

[44]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[46]  S. Cocklin,et al.  Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. , 2012, Journal of medicinal chemistry.

[47]  R. König,et al.  SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-Goutières Syndrome Are Highly Susceptible to HIV-1 Infection , 2011, PLoS pathogens.

[48]  Thomas Hollis,et al.  Aicardi-Goutières Syndrome Gene and HIV-1 Restriction Factor SAMHD1 Is a dGTP-regulated Deoxynucleotide Triphosphohydrolase*♦ , 2011, The Journal of Biological Chemistry.

[49]  Geoff Kelly,et al.  HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase , 2011, Nature.

[50]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[51]  S. Schmidt,et al.  Endogenous CD317/Tetherin Limits Replication of HIV-1 and Murine Leukemia Virus in Rodent Cells and Is Resistant to Antagonists from Primate Viruses , 2010, Journal of Virology.

[52]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[53]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[54]  J. Issa,et al.  Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. , 2009, Blood.

[55]  J. Dipersio,et al.  Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) , 2008, Cancer Chemotherapy and Pharmacology.

[56]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[58]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Brown,et al.  Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. , 2006, Biophysical journal.

[60]  G. Marcucci,et al.  Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes , 2005, Journal of clinical pharmacology.

[61]  Fei Long,et al.  REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. , 2004, Acta crystallographica. Section D, Biological crystallography.

[62]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[63]  M. Goldsmith,et al.  Susceptibility of Rat-Derived Cells to Replication by Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[64]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[65]  L H Li,et al.  Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.

[66]  W. Neil.  Where do we draw the line , 1966 .